ATE169915T1 - Pyrimidindionderivate, deren herstellung und verwendung - Google Patents

Pyrimidindionderivate, deren herstellung und verwendung

Info

Publication number: ATE169915T1
Authority: AT; Austria
Prior art keywords: hydrogen; substituted; residue; hydrocarbon residue; diseases
Prior art date: 1990-02-15

Application number

AT91102020T

Other languages

English (en)

Inventor

Takehiko Naka

Kohei Nishikawa

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-02-15

Filing date

1991-02-13

Publication date

1998-09-15

1991-02-13 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

1998-09-15 Application granted granted Critical

1998-09-15 Publication of ATE169915T1 publication Critical patent/ATE169915T1/de

Links

150000008512 pyrimidinediones Chemical class 0.000 title abstract 2
125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
150000001450 anions Chemical class 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical class 0.000 abstract 2
150000002431 hydrogen Chemical class 0.000 abstract 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
125000006850 spacer group Chemical group 0.000 abstract 2
102000005862 Angiotensin II Human genes 0.000 abstract 1
101800000733 Angiotensin-2 Proteins 0.000 abstract 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
-1 amino, formyl Chemical group 0.000 abstract 1
229950006323 angiotensin ii Drugs 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
208000019622 heart disease Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT91102020T 1990-02-15 1991-02-13 Pyrimidindionderivate, deren herstellung und verwendung ATE169915T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP3491990		1990-02-15

Publications (1)

Publication Number	Publication Date
ATE169915T1 true ATE169915T1 (de)	1998-09-15

Family

ID=12427624

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT91102020T ATE169915T1 (de)	1990-02-15	1991-02-13	Pyrimidindionderivate, deren herstellung und verwendung

Country Status (5)

Country	Link
US (1)	US5162326A (de)
EP (1)	EP0442473B1 (de)
AT (1)	ATE169915T1 (de)
CA (1)	CA2036304C (de)
DE (1)	DE69129998T2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5250548A (en) *	1990-09-10	1993-10-05	Abbott Laboratories	Angiotensin II receptor antagonists
US5182288A (en) *	1991-11-13	1993-01-26	Ortho Pharmaceutical Corporation	Substituted n-biphenylyl lactams
TW284688B (de) *	1991-11-20	1996-09-01	Takeda Pharm Industry Co Ltd
US5350752A (en) *	1991-12-16	1994-09-27	E. R. Squibb & Sons, Inc.	Dihydropyrimidine derivatives
DE4227773A1 (de) *	1992-08-23	1994-02-24	Merck Patent Gmbh	Di- bzw. Triazindione
CA2115985A1 (en) *	1993-02-25	1994-08-26	Kohei Nishikawa	Vascular hypertrophy suppressor
JP3810020B2 (ja) *	1993-04-22	2006-08-16	武田薬品工業株式会社	腎疾患の予防または治療剤
US5721263A (en) *	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
CZ154994A3 (en) *	1993-07-02	1995-09-13	Senju Pharma Co	Visual hypotensive agent
US5391541A (en) *	1993-08-11	1995-02-21	Fmc Corporation	Herbicidal 3-(substituted-benzyl)-1-methyl-6-trifluoromethyluracils
KR0151811B1 (ko) *	1993-12-21	1998-10-15	강박광	신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법
KR20010086245A (ko)	1998-03-04	2001-09-10	다케다 야쿠힌 고교 가부시키가이샤	Ａⅱ 길항제용 서방성 제제, 그것의 제조 및 용도
SE9903028D0 (sv)	1999-08-27	1999-08-27	Astra Ab	New use
US6613469B2 (en) *	2000-12-22	2003-09-02	Delphi Technologies, Inc.	Fluid distribution surface for solid oxide fuel cells
AU2002344813A1 (en) *	2001-06-15	2003-01-02	University Of Massachusetts	Methods for synthesizing substituted pyrimidines
US7812044B2 (en)	2001-11-13	2010-10-12	Takeda Pharmaceutical Company Limited	Anticancer agents
US7232828B2 (en)	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN102127057A (zh) *	2004-03-15	2011-07-20	武田药品工业株式会社	二肽基肽酶抑制剂
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
JP2009544710A (ja) *	2006-07-24	2009-12-17	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖ逆転写酵素インヒビター
US7803940B2 (en) *	2006-11-24	2010-09-28	Takeda Pharmaceutical Company Limited	Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
JP2010510962A (ja) *	2006-11-24	2010-04-08	武田薬品工業株式会社	複素単環化合物およびその用途
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2151440A4 (de) *	2007-05-21	2010-10-20	Takeda Pharmaceutical	Heterocyclische verbindung und ihre verwendung
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (de)	2007-06-04	2015-10-28	Synergy Pharmaceuticals Inc.	Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
CN101784532B (zh) *	2007-06-29	2014-10-22	韩国化学研究院	Hiv逆转录酶抑制剂
KR20100041798A (ko) *	2007-06-29	2010-04-22	한국화학연구원	신규 ｈｉｖ 역전사효소 억제제
DK2203430T3 (da)	2007-09-17	2011-09-26	Abbott Lab	N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
SI2368882T1 (sl) *	2007-09-17	2015-02-27	Abbvie Bahamas Ltd.	Antiinfekcijski pirimidini in njihove uporabe
MY162760A (en)	2007-09-17	2017-07-14	Abbvie Bahamas Ltd	Anti-infective agents and uses thereof
WO2009085797A1 (en) *	2007-12-21	2009-07-09	Gilead Sciences, Inc.	Processes for preparing hiv reverse transcriptase inhibitors
EP2810951B1 (de)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
EP3241839B1 (de)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
US9216952B2 (en) *	2010-03-23	2015-12-22	Abbvie Inc.	Process for preparing antiviral compound
US9255074B2 (en)	2010-07-16	2016-02-09	Abbvie Inc.	Process for preparing antiviral compounds
BR112013001138A2 (pt)	2010-07-16	2016-07-05	Abbvie Inc	ligantes de fosfina para reações catalíticas
US8895737B2 (en)	2010-07-16	2014-11-25	Shashank Shekhar	Process for preparing antiviral compounds
US8975443B2 (en)	2010-07-16	2015-03-10	Abbvie Inc.	Phosphine ligands for catalytic reactions
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
SI3004138T1 (sl)	2013-06-05	2024-07-31	Bausch Health Ireland Limited	Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
CN117820248A (zh)	2021-04-14	2024-04-05	盐野义制药株式会社	具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5671073A (en) *	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	Imidazole derivative
JPS5671074A (en) *	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4812462A (en) *	1986-04-01	1989-03-14	Warner-Lambert Company	4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (en) *	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
US4820843A (en) *	1987-05-22	1989-04-11	E. I. Du Pont De Nemours And Company	Tetrazole intermediates to antihypertensive compounds
US5015651A (en) *	1988-01-07	1991-05-14	E. I. Du Pont De Nemours And Company	Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) *	1988-01-07	1989-11-14	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking benzimidazoles

1991
- 1991-02-13 US US07/654,490 patent/US5162326A/en not_active Expired - Fee Related
- 1991-02-13 EP EP91102020A patent/EP0442473B1/de not_active Expired - Lifetime
- 1991-02-13 CA CA002036304A patent/CA2036304C/en not_active Expired - Fee Related
- 1991-02-13 AT AT91102020T patent/ATE169915T1/de not_active IP Right Cessation
- 1991-02-13 DE DE69129998T patent/DE69129998T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0442473B1 (de)	1998-08-19
DE69129998T2 (de)	1998-12-24
CA2036304A1 (en)	1991-08-16
US5162326A (en)	1992-11-10
EP0442473A1 (de)	1991-08-21
DE69129998D1 (de)	1998-09-24
CA2036304C (en)	2001-04-17

Legal Events

Date	Code	Title	Description
1999-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69129998D1 (de)	1998-09-24	Pyrimidindionderivate, deren Herstellung und Verwendung
DE69120100D1 (de)	1996-07-18	Annelierte Thiophen-Derivate, ihre Herstellung und Verwendung
DE69110320D1 (de)	1995-07-20	Stickstoff enthaltende heterozyklische Verbindungen, ihre Herstellung und Verwendung.
DE68920654D1 (de)	1995-03-02	4-Oxochinolin-3-carbonsäure-Derivate, ihre Herstellung und ihre Verwendung.
KR900700465A (ko)	1990-08-13	화합물
ATE105554T1 (de)	1994-05-15	Benzazol-derivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
PH25859A (en)	1991-12-02	Composition for treatment of ischemic disorder
ATE134633T1 (de)	1996-03-15	Thienoimidazolderivate, ihre herstellung und verwendung
AR002761A1 (es)	1998-04-29	Un compuesto derivado del triazol, su uso, una composicion farmaceutica que lo contiene, un metodo de tratamiento o prevencion de una infeccion fungica enun paciente humano mediante dicho compuesto o composicion, y procedimiento y compuestos intermedios para prepararlo.
DK0648760T3 (da)	1999-09-13	Triazinderivat og dets fremstilling og anvendelse
NO934741L (no)	1994-06-24	Fremgangsmåte for minimalisering og kontroll av ischemiske og reperfusjonsskade
DE3675431D1 (de)	1990-12-13	1,3-oxathianderivate.
AU590748B2 (en)	1989-11-16	Benzo(C)-1,5-naphthyridines, a process and intermediates for their preparation and their use as medicaments
ATE91487T1 (de)	1993-07-15	Dibenzodioxazecin- und dibenzodioxaazacycloundecin-derivate.